[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Health Care Stocks Fall as Trump Eyes 'Middlemen'",
    "summary": "The S&P 500 slid 0.4% on Tuesday, Sept. 17, as stocks faltered ahead of Wednesday's Federal Reserve's interest rate announcement.",
    "url": "https://finnhub.io/api/news?id=aa49d078b395858fd5879744864e4aa71490e0cf73dc78f0b1d7b6f8b904701f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734473451,
      "headline": "S&P 500 Gains and Losses Today: Health Care Stocks Fall as Trump Eyes 'Middlemen'",
      "id": 132034902,
      "image": "https://www.investopedia.com/thmb/da47nBHkdVs2i-uBT-QjtTX4oxo=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/INV_HumanaBuilding_GettyImages-148448576-4f80a4a42be344558c9f3f7df7094384.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The S&P 500 slid 0.4% on Tuesday, Sept. 17, as stocks faltered ahead of Wednesday's Federal Reserve's interest rate announcement.",
      "url": "https://finnhub.io/api/news?id=aa49d078b395858fd5879744864e4aa71490e0cf73dc78f0b1d7b6f8b904701f"
    }
  },
  {
    "ts": null,
    "headline": "US Equities Markets End Lower Tuesday as Federal Reserve Begins Meeting",
    "summary": "US benchmark equity indexes ended lower Tuesday as the Federal Reserve kicked off its two-day moneta",
    "url": "https://finnhub.io/api/news?id=d7b06836c128abdeac422f1292f1812f4c6aa3bd2adf60d76d850d82fac9e0d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734469253,
      "headline": "US Equities Markets End Lower Tuesday as Federal Reserve Begins Meeting",
      "id": 132035729,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes ended lower Tuesday as the Federal Reserve kicked off its two-day moneta",
      "url": "https://finnhub.io/api/news?id=d7b06836c128abdeac422f1292f1812f4c6aa3bd2adf60d76d850d82fac9e0d7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?",
    "summary": "With cost cuts, steady revenue projections, and a push for new growth, Pfizer aims to bounce back in 2025.",
    "url": "https://finnhub.io/api/news?id=0babef508c4cd7231c97a938783819ae80ff874f74f858fe5d98c6bc67bd2cfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734456499,
      "headline": "Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?",
      "id": 132035730,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/808431929aeb6d847eefb98fc2f80936",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With cost cuts, steady revenue projections, and a push for new growth, Pfizer aims to bounce back in 2025.",
      "url": "https://finnhub.io/api/news?id=0babef508c4cd7231c97a938783819ae80ff874f74f858fe5d98c6bc67bd2cfc"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Drop After Retail Sales Jump in Seasonally Strong November",
    "summary": "US equity indexes fell around midday Tuesday after retail sales grew more than forecast and as the F",
    "url": "https://finnhub.io/api/news?id=99b572b23da1e5ccc1e54355f774beab395cc2607b0b1083700189c7b269f4b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734455935,
      "headline": "US Equity Indexes Drop After Retail Sales Jump in Seasonally Strong November",
      "id": 132028405,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US equity indexes fell around midday Tuesday after retail sales grew more than forecast and as the F",
      "url": "https://finnhub.io/api/news?id=99b572b23da1e5ccc1e54355f774beab395cc2607b0b1083700189c7b269f4b1"
    }
  },
  {
    "ts": null,
    "headline": "The Take On Tyra Biosciences",
    "summary": "Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.",
    "url": "https://finnhub.io/api/news?id=1989fef2977fc61d12075dedb7f7a4cf77cf88bac5a05fa7e2f102baf15ad002",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734455615,
      "headline": "The Take On Tyra Biosciences",
      "id": 132030976,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.",
      "url": "https://finnhub.io/api/news?id=1989fef2977fc61d12075dedb7f7a4cf77cf88bac5a05fa7e2f102baf15ad002"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=8dea032320672e33b79bdf4a5af4b40a37c1075518913b1d6cc3fb724ed0a311",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734453540,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 132066914,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=8dea032320672e33b79bdf4a5af4b40a37c1075518913b1d6cc3fb724ed0a311"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook",
    "summary": "Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook",
    "url": "https://finnhub.io/api/news?id=bd3c303930160431394ce8544324e9d756bf17322bc52e2c9d954127ed2041a2",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734451594,
      "headline": "Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook",
      "id": 132066892,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook",
      "url": "https://finnhub.io/api/news?id=bd3c303930160431394ce8544324e9d756bf17322bc52e2c9d954127ed2041a2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Shares Jump 4% on Positive 2025 Outlook Despite $1B Impact",
    "summary": "Pfizer Confirms Strong 2024 Outlook, Sees $1B Impact from Medicare Changes",
    "url": "https://finnhub.io/api/news?id=ee9a888c79133e363403abdfe7e6cf682ffaf8db1801e581d10dc7d080b36a74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734451436,
      "headline": "Pfizer Shares Jump 4% on Positive 2025 Outlook Despite $1B Impact",
      "id": 132035732,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/9c51ffa77feb6514a0ead7f465ea002f",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Confirms Strong 2024 Outlook, Sees $1B Impact from Medicare Changes",
      "url": "https://finnhub.io/api/news?id=ee9a888c79133e363403abdfe7e6cf682ffaf8db1801e581d10dc7d080b36a74"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Rises as 2025 Outlook in Line With Expectations",
    "summary": "Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.",
    "url": "https://finnhub.io/api/news?id=7febd37ba478a9d4c797f33e42f67e07debd2e25d1faed8ed19f48a4a437140b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734450263,
      "headline": "Pfizer Stock Rises as 2025 Outlook in Line With Expectations",
      "id": 132035733,
      "image": "https://www.investopedia.com/thmb/rf39BdkszXwjukwHgThcIuCRorM=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc():focal(4992x3749:4994x3751)/GettyImages-2160341079-3d9f53b3d3d14b0ab294d304b3d093dc.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.",
      "url": "https://finnhub.io/api/news?id=7febd37ba478a9d4c797f33e42f67e07debd2e25d1faed8ed19f48a4a437140b"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Quantum Stocks Manic",
    "summary": "Quantum computing stocks are Wall Street's new momentum darlings. Retail sales top expectations. (Meta updating Ray-Bans will live AI.",
    "url": "https://finnhub.io/api/news?id=c598c9ed6f9b8f336b14379c6d43f44c4c0ab057f7836be51f45b78691f8f258",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734450240,
      "headline": "Wall Street Lunch: Quantum Stocks Manic",
      "id": 132029633,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1980358472/image_1980358472.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Quantum computing stocks are Wall Street's new momentum darlings. Retail sales top expectations. (Meta updating Ray-Bans will live AI.",
      "url": "https://finnhub.io/api/news?id=c598c9ed6f9b8f336b14379c6d43f44c4c0ab057f7836be51f45b78691f8f258"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer issues 2025 outlook in-line with Wall Street, shares rise",
    "summary": "Pfizer's (PFE) stock moved higher in Tuesday's pre-market trading after the pharmaceutical giant issued an upbeat full-year outlook for 2025. The company projected annual sales between $61 billion and $64 billion, with earnings per share estimates at $2.80 to $3 — both metrics coming in line with Wall Street projections. Additionally, the company reaffirmed its 2024 full-year guidance, estimating earnings per share between $2.75 and $2.95. Market Domination hosts Julie Hyman and Josh Lipton break down the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith",
    "url": "https://finnhub.io/api/news?id=3c04906f14d79f640c2aa63647b9176cad2fa1bbfdb28cdc16b0c1eae39119ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734448162,
      "headline": "Pfizer issues 2025 outlook in-line with Wall Street, shares rise",
      "id": 132035734,
      "image": "https://s.yimg.com/ny/api/res/1.2/tPA4VwJCl7mCHXwy2j7jZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/76365510-bc81-11ef-9fef-525fcfdc5e9f",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's (PFE) stock moved higher in Tuesday's pre-market trading after the pharmaceutical giant issued an upbeat full-year outlook for 2025. The company projected annual sales between $61 billion and $64 billion, with earnings per share estimates at $2.80 to $3 — both metrics coming in line with Wall Street projections. Additionally, the company reaffirmed its 2024 full-year guidance, estimating earnings per share between $2.75 and $2.95. Market Domination hosts Julie Hyman and Josh Lipton break down the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith",
      "url": "https://finnhub.io/api/news?id=3c04906f14d79f640c2aa63647b9176cad2fa1bbfdb28cdc16b0c1eae39119ea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Eyes 2025 Earnings Growth as CEO Touts 'Discipline'",
    "summary": "Pfizer (PFE) projected higher earnings for 2025 and revenue in line with this year's likely result a",
    "url": "https://finnhub.io/api/news?id=44ed22be17f1a9f05540d563b73eb22a41c011b8bde9b25530bf0af0c598d274",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734445867,
      "headline": "Pfizer Eyes 2025 Earnings Growth as CEO Touts 'Discipline'",
      "id": 132035735,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/d93ce51bddbc90991886c8de38019462",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) projected higher earnings for 2025 and revenue in line with this year's likely result a",
      "url": "https://finnhub.io/api/news?id=44ed22be17f1a9f05540d563b73eb22a41c011b8bde9b25530bf0af0c598d274"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Signals Growth in FY 2025 Guidance, Projects Revenue Up to $64 Billion",
    "summary": "Pfizer Provides Positive Signs in Financial Outlook, Driven by Cost Realignment and Manufacturing Management",
    "url": "https://finnhub.io/api/news?id=94463ae29a627b800d04e48988866c88c649ced997dde6a7427a48e8cb1ef920",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734444504,
      "headline": "Pfizer Signals Growth in FY 2025 Guidance, Projects Revenue Up to $64 Billion",
      "id": 132035736,
      "image": "https://s.yimg.com/ny/api/res/1.2/LtDRrn.pCFlCkdaClzYgEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01Mjk-/https://media.zenfs.com/en/us.finance.gurufocus/896904febd776c0eb87d0b1509bf1053",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Provides Positive Signs in Financial Outlook, Driven by Cost Realignment and Manufacturing Management",
      "url": "https://finnhub.io/api/news?id=94463ae29a627b800d04e48988866c88c649ced997dde6a7427a48e8cb1ef920"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's stock heads for the top of the S&P 500's gainers after earnings outlook",
    "summary": "Pfizer's stock heads for the top of the S&P 500's gainers after earnings outlook",
    "url": "https://finnhub.io/api/news?id=7d03582efde3ba9704bbb54099dd2324a0f63e6c0b2fac88e00ed99365dd0604",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734441805,
      "headline": "Pfizer's stock heads for the top of the S&P 500's gainers after earnings outlook",
      "id": 132064539,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer's stock heads for the top of the S&P 500's gainers after earnings outlook",
      "url": "https://finnhub.io/api/news?id=7d03582efde3ba9704bbb54099dd2324a0f63e6c0b2fac88e00ed99365dd0604"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sees 2025 Revenue in Line With Wall Street Views",
    "summary": "Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits.",
    "url": "https://finnhub.io/api/news?id=f0cd5d8e54d3f48ce2aa429364ce7116ae03715d06e78c86f4274b54430ddb63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734438720,
      "headline": "Pfizer Sees 2025 Revenue in Line With Wall Street Views",
      "id": 132024682,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits.",
      "url": "https://finnhub.io/api/news?id=f0cd5d8e54d3f48ce2aa429364ce7116ae03715d06e78c86f4274b54430ddb63"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion",
    "summary": "The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.",
    "url": "https://finnhub.io/api/news?id=c7b842ceb48f22af73dcc8aed1570fd26832fe9070d4fe49fd3c4e58e9b4c4dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734438000,
      "headline": "Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion",
      "id": 132024683,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.",
      "url": "https://finnhub.io/api/news?id=c7b842ceb48f22af73dcc8aed1570fd26832fe9070d4fe49fd3c4e58e9b4c4dc"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
    "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at some […]",
    "url": "https://finnhub.io/api/news?id=19ff805306c866569aef48101806926ce225136457f24060a0e03fb977537fca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734437747,
      "headline": "Is Pfizer Inc. (PFE) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
      "id": 132024685,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at some […]",
      "url": "https://finnhub.io/api/news?id=19ff805306c866569aef48101806926ce225136457f24060a0e03fb977537fca"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s In-Line Guidance Offers Relief to Weary Investors",
    "summary": "(Bloomberg) -- Pfizer Inc. forecast 2025 sales and earnings in line with analysts’ projections, a step toward fending off an activist investor’s claims that the drugmaker is being mismanaged.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfLondon’s Tube Fares Are Set to Rise by 4.6% Next YearRevenue next year will be $61 billion to $64 billion, Pfizer said Tuesday in a statement, while Wall Street analysts surveyed by Bloomber",
    "url": "https://finnhub.io/api/news?id=6fc91080b61c5963b394532cb484077a4c1570e2914d26697bd8b141e4f9027f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734437624,
      "headline": "Pfizer’s In-Line Guidance Offers Relief to Weary Investors",
      "id": 132024686,
      "image": "https://s.yimg.com/ny/api/res/1.2/spInDTOllB.Xfpit9sRqzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/d61e12834f4acc440fcda2c83de25877",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Pfizer Inc. forecast 2025 sales and earnings in line with analysts’ projections, a step toward fending off an activist investor’s claims that the drugmaker is being mismanaged.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfLondon’s Tube Fares Are Set to Rise by 4.6% Next YearRevenue next year will be $61 billion to $64 billion, Pfizer said Tuesday in a statement, while Wall Street analysts surveyed by Bloomber",
      "url": "https://finnhub.io/api/news?id=6fc91080b61c5963b394532cb484077a4c1570e2914d26697bd8b141e4f9027f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer 2025 profit forecast soothes investor jitters as it pursues turnaround",
    "summary": "After the immense success of its COVID products during the pandemic years, the company is facing pressure to bring new drugs to the market to make up for the potential revenue loss from some of its top sellers that are likely to go off patent soon.  Analysts over the past few weeks have also cut their estimates for Pfizer's profit.  Pfizer CEO Albert Bourla, however, has defended his turnaround strategy as the company launches cost-cutting programs and sheds non-core businesses to pay down debt.",
    "url": "https://finnhub.io/api/news?id=1db40ea07867b91865a6e3774ed69e314f13eef493b98d542232fc8884ccb816",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436603,
      "headline": "Pfizer 2025 profit forecast soothes investor jitters as it pursues turnaround",
      "id": 132024688,
      "image": "https://media.zenfs.com/en/reuters-finance.com/f0d24c1fc4682d8a9820338db2582151",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After the immense success of its COVID products during the pandemic years, the company is facing pressure to bring new drugs to the market to make up for the potential revenue loss from some of its top sellers that are likely to go off patent soon.  Analysts over the past few weeks have also cut their estimates for Pfizer's profit.  Pfizer CEO Albert Bourla, however, has defended his turnaround strategy as the company launches cost-cutting programs and sheds non-core businesses to pay down debt.",
      "url": "https://finnhub.io/api/news?id=1db40ea07867b91865a6e3774ed69e314f13eef493b98d542232fc8884ccb816"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance",
    "summary": "NEW YORK, December 17, 2024--Pfizer 2025 Financial Guidance press release",
    "url": "https://finnhub.io/api/news?id=594f0398d8d59dc706250b57c33d3da698b66d7772f3e983b83798e1da77f8e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734435900,
      "headline": "Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance",
      "id": 132024689,
      "image": "https://media.zenfs.com/en/business-wire.com/4867c62f304be0c198f8dc9379e3c3cb",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 17, 2024--Pfizer 2025 Financial Guidance press release",
      "url": "https://finnhub.io/api/news?id=594f0398d8d59dc706250b57c33d3da698b66d7772f3e983b83798e1da77f8e3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)",
    "summary": "Pfizer Inc. (NYSE:PFE) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ETCompany ParticipantsFrancesca DeMartino - Chief IRO and...",
    "url": "https://finnhub.io/api/news?id=12a1693df55123d47af5ab1eca81c8ae4ec38f177eff9ad3921fc769b7f28da7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734435435,
      "headline": "Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)",
      "id": 132026291,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. (NYSE:PFE) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ETCompany ParticipantsFrancesca DeMartino - Chief IRO and...",
      "url": "https://finnhub.io/api/news?id=12a1693df55123d47af5ab1eca81c8ae4ec38f177eff9ad3921fc769b7f28da7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer predicts stability, to Wall Street’s relief",
    "summary": "The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty caused by COVID [is] mostly resolved,” its CFO said.",
    "url": "https://finnhub.io/api/news?id=8395ce69f07627d97b49b9e634249d80b543783864ebb3eeca02573944834af4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734434880,
      "headline": "Pfizer predicts stability, to Wall Street’s relief",
      "id": 132035737,
      "image": "https://imgproxy.divecdn.com/FdnOw-9MjS8hM1h86X-3aKcJKAlBzhtnOS8LFv1o9qw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDkxNDg0MDMxLmpwZw==.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty caused by COVID [is] mostly resolved,” its CFO said.",
      "url": "https://finnhub.io/api/news?id=8395ce69f07627d97b49b9e634249d80b543783864ebb3eeca02573944834af4"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: 2 Stocks That'll Be Worth More Than Palantir 5 Years From Now",
    "summary": "Palantir Technologies (NASDAQ: PLTR) is the hands-down winner.  Thanks to this impressive performance, Palantir's market cap now hovers around $165 billion.  Here are two stocks I predict will be worth more than Palantir five years from now.",
    "url": "https://finnhub.io/api/news?id=a6995d4f8f4644cecccd2a4a39e3301ecbfd63b907b247d978c21eca1eec4b90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734433620,
      "headline": "Prediction: 2 Stocks That'll Be Worth More Than Palantir 5 Years From Now",
      "id": 132024690,
      "image": "https://g.foolcdn.com/editorial/images/801155/intuitive-da-vinci-or-staff-with-patient-cart-hi-res.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Palantir Technologies (NASDAQ: PLTR) is the hands-down winner.  Thanks to this impressive performance, Palantir's market cap now hovers around $165 billion.  Here are two stocks I predict will be worth more than Palantir five years from now.",
      "url": "https://finnhub.io/api/news?id=a6995d4f8f4644cecccd2a4a39e3301ecbfd63b907b247d978c21eca1eec4b90"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer shares rise despite criticism Starboard, with optimistic 2025 earnings forecast",
    "summary": "Copyright © BusinessAMBE 2023Key takeawaysPfizer's share price rose nearly 3 percent in pretrading.The company expects adjusted earnings between $2.80 and $3 per share for 2025.Pfizer's...",
    "url": "https://finnhub.io/api/news?id=a9d7ed88b9fa50fef1b37976084e6f7d049711186754950398438fe57c892e8c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734429689,
      "headline": "Pfizer shares rise despite criticism Starboard, with optimistic 2025 earnings forecast",
      "id": 132025185,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Copyright © BusinessAMBE 2023Key takeawaysPfizer's share price rose nearly 3 percent in pretrading.The company expects adjusted earnings between $2.80 and $3 per share for 2025.Pfizer's...",
      "url": "https://finnhub.io/api/news?id=a9d7ed88b9fa50fef1b37976084e6f7d049711186754950398438fe57c892e8c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2025 Financial Guidance Press Release",
    "summary": "For Immediate Release Media Contact: PfizerMediaRelations@Pfizer.com ...",
    "url": "https://finnhub.io/api/news?id=4cd3eed18d976bda050e07777c334fe6b460bd129cf1358e79cb82ed741c8a0e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734428110,
      "headline": "Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2025 Financial Guidance Press Release",
      "id": 132024906,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "For Immediate Release Media Contact: PfizerMediaRelations@Pfizer.com ...",
      "url": "https://finnhub.io/api/news?id=4cd3eed18d976bda050e07777c334fe6b460bd129cf1358e79cb82ed741c8a0e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2025 Financial Guidance Presentation",
    "summary": "Pfizer Provides Full-Year 2025 Financial Guidance December 17, 2024 1 Introduction ...",
    "url": "https://finnhub.io/api/news?id=ae878a72ef89e911eaec859f2a57788d6257a27f6e9081fc5dab021d667d67c5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734428109,
      "headline": "Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2025 Financial Guidance Presentation",
      "id": 132024907,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Provides Full-Year 2025 Financial Guidance December 17, 2024 1 Introduction ...",
      "url": "https://finnhub.io/api/news?id=ae878a72ef89e911eaec859f2a57788d6257a27f6e9081fc5dab021d667d67c5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2025 Financial Guidance Event Announcement",
    "summary": "For Immediate Release Media Contact: PfizerMediaRelations@Pfizer.com ...",
    "url": "https://finnhub.io/api/news?id=24d7958473bd838b7b738c78b741619a67143aa6733467c43740a584ce587451",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734427987,
      "headline": "Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2025 Financial Guidance Event Announcement",
      "id": 132024885,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "For Immediate Release Media Contact: PfizerMediaRelations@Pfizer.com ...",
      "url": "https://finnhub.io/api/news?id=24d7958473bd838b7b738c78b741619a67143aa6733467c43740a584ce587451"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sees 2025 Revenue in Line With Wall Street Views -- Update",
    "summary": "By Sabela Ojea Pfizer forecast 2025 revenue and earnings in line with market expectations, despite an expected $1 billion hit from the redesign of federal drug benefits. The guidance comes...",
    "url": "https://finnhub.io/api/news?id=54965530792652f32c350e792b2bae3e6eba2aa148b5fc0e90211cc4a557d8f9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734423435,
      "headline": "Pfizer Sees 2025 Revenue in Line With Wall Street Views -- Update",
      "id": 132024083,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Pfizer forecast 2025 revenue and earnings in line with market expectations, despite an expected $1 billion hit from the redesign of federal drug benefits. The guidance comes...",
      "url": "https://finnhub.io/api/news?id=54965530792652f32c350e792b2bae3e6eba2aa148b5fc0e90211cc4a557d8f9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: 2025 targets unveiled, 2024 forecasts confirmed",
    "summary": "Pfizer is expected to rise on Tuesday on Wall Street after unveiling 2025 targets broadly in line with market forecasts.The US pharmaceuticals group said this morning that it expected adjusted...",
    "url": "https://finnhub.io/api/news?id=ece880abfd85ae8107fce81c6a3ea85d954b65462c0645388629637e583f8435",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734422653,
      "headline": "Pfizer: 2025 targets unveiled, 2024 forecasts confirmed",
      "id": 132023989,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer is expected to rise on Tuesday on Wall Street after unveiling 2025 targets broadly in line with market forecasts.The US pharmaceuticals group said this morning that it expected adjusted...",
      "url": "https://finnhub.io/api/news?id=ece880abfd85ae8107fce81c6a3ea85d954b65462c0645388629637e583f8435"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Provides Full Year 2025 Guidance and Reaffirms Full Year 2024 Guidance Form 8 K",
    "summary": "Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance ▪Full-Year 2025 Revenue Guidance Range of $61.0 to $64.0 Billion ▪Full-Year 2025...",
    "url": "https://finnhub.io/api/news?id=b99f61fa1899f317d16514882307cf1031446fc974707b94808e30506781b5b6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734421865,
      "headline": "Pfizer : Provides Full Year 2025 Guidance and Reaffirms Full Year 2024 Guidance Form 8 K",
      "id": 132023805,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance ▪Full-Year 2025 Revenue Guidance Range of $61.0 to $64.0 Billion ▪Full-Year 2025...",
      "url": "https://finnhub.io/api/news?id=b99f61fa1899f317d16514882307cf1031446fc974707b94808e30506781b5b6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sees 2025 Revenue in Line With Wall Street Views, Despite Hit from Benefit Changes",
    "summary": "By Sabela Ojea Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits. The New York pharmaceutical...",
    "url": "https://finnhub.io/api/news?id=c0d721fb5a845173ac297354e52bcacbaaa8ebfa3cdcd7bc330f277512972592",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734421093,
      "headline": "Pfizer Sees 2025 Revenue in Line With Wall Street Views, Despite Hit from Benefit Changes",
      "id": 132023657,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits. The New York pharmaceutical...",
      "url": "https://finnhub.io/api/news?id=c0d721fb5a845173ac297354e52bcacbaaa8ebfa3cdcd7bc330f277512972592"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer forecasts 2025 profit in line with expectations",
    "summary": "Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be roughly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist...",
    "url": "https://finnhub.io/api/news?id=4785f7606c06cbac0d755b5543ca536e43033cfad3aa69fb117824e2703f0d13",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734418603,
      "headline": "Pfizer forecasts 2025 profit in line with expectations",
      "id": 132023250,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be roughly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist...",
      "url": "https://finnhub.io/api/news?id=4785f7606c06cbac0d755b5543ca536e43033cfad3aa69fb117824e2703f0d13"
    }
  }
]